Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tymara Berry

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical and Translational Science|December 14, 2025
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic SyndromesAshley L Lennox, Fei Huang, Mario González-Sales, et al.
Clinical and Translational Science|February 20, 2025
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational AnalysisAshley L Lennox, Libo Sun, Fei Huang, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 21, 2024
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitorMario González-Sales, Ashley L Lennox, Fei Huang, et al.
Clinical and Translational Science|November 18, 2024
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational scienceAshley L Lennox, Fei Huang, Melissa Kelly Behrs, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.
Haematologica|January 22, 2026
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge studyMikkael A Sekeres, Amer M Zeidan, Valeria Santini, et al.
Leukemia|January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstatValeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical and Translational Science|December 14, 2025
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic SyndromesAshley L Lennox, Fei Huang, Mario González-Sales, et al.
Clinical and Translational Science|February 20, 2025
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational AnalysisAshley L Lennox, Libo Sun, Fei Huang, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 21, 2024
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitorMario González-Sales, Ashley L Lennox, Fei Huang, et al.
Clinical and Translational Science|November 18, 2024
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational scienceAshley L Lennox, Fei Huang, Melissa Kelly Behrs, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.
Haematologica|January 22, 2026
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge studyMikkael A Sekeres, Amer M Zeidan, Valeria Santini, et al.
Leukemia|January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstatValeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Pageof 2